NEWS & VIEWS

Global private equity and venture capital news and research

Warburg Pincus set to get 3x return from Bausch & Lomb sale

28 May 2013

contact lensValeant Pharmaceuticals has acquired contact lens maker Bausch and Lomb from Warburg Pincus for $8.7bn in cash, giving the New York-based buyout major a return of three times.

Under the deal, Valeant will pay &8.7bn, of which Warburg will receive $4.5bn and $4.2bn will be used to repay Bausch and Lomb’s outstanding debt.

Warburg will receive a return of around three times on its $1.7bn equity investment made in Bausch in 2007, according to Bloomberg’s estimates based on a takeover value of $9bn.

Valeant said it expects the deal to result in annual cost savings of $800m by the end of 2014.

Bausch expects to post an EBITDA of $720m on revenues of $3.3bn this year.

CEO of Bausch and Lomb Brent Saunders said, “Bausch + Lomb has undergone a profound transformation over the last few years.

“We introduced innovative new products for patients; built a robust pipeline; expanded into new markets; and strengthened our relationships with eye care professionals around the world.”

Earlier this year it was reported that the company was looking to raise $100m via an IPO and that Warburg was still considering a private sale of the company and had hired Goldman Sachs to find a suitor.

Warburg Pincus has invested over $8.1bn in more than 140 healthcare companies.

Copyright © 2013 AltAssets

FUNDRAISING & INVESTOR RELATIONS


Legals & Terms of UsePrivacy Policy


AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: Zetland House, 5-25 Scrutton St, London EC2A 4HJ
Content is © AltAssets 2000-2014